PRLog - Jun. 13, 2014 - CHICAGO -- . The Janet Davison Rowley Patient Impact Researcher Award will be given to one or more researchers who have created positive patient impact through Rediscovery Research™, repurposing an existing, approved drug or device for a new patient population. The BAM event will take place on June 17th, 2014 at the Standard Club in Chicago.
Dr. Janet Davison Rowley
Dr. Janet Rowley is legendary for her discoveries in cancer genetics. In her biography in the National Library of Medicine, Dr. Janet Davison Rowley said, “In research, I had the extraordinary good fortune to make a series of discoveries about genetic changes in human leukemia and lymphoma. Today, the 9;22 translocation in chronic myelogenous leukemia is treated with a specific drug, Gleevec©, that induces remissions in the vast majority of patients. To have contributed to this marvelous success story is truly a rewarding experience.”
Since its initial approval, Gleevec has been approved for repurposed uses in patients with different types of gastrointestinal tumors. Scientists continue to study the drug's effectiveness in other cancers, and in endocrine diseases, cardiovascular diseases, musculoskeletal diseases, and rare genetic diseases. Dr. Rowley’s genetics discoveries, when combined with the work of others, have created a blueprint for the development of new drugs and the ability to find new indications for already approved drugs.
Dr. Rowley spent most of her distinguished career at the University of Chicago, one of Cures Within Reach’s academic research partner institutions. 2014 recipients of this award will be Dr. D. James Surmeier and Dr. Tanya Simuni of Northwestern University, honored for their work repurposing an existing, approved drug as a therapy for Parkinson’s Disease.
BAM 2014 will also recognize Dr. Norbert Riedel (http://www.cureswithinreach.org/
Sponsors for BAM include Takeda Pharmaceuticals, Baxter International Inc. and Forest City Sceince+Technology Group. Chairs for 2014 are Nancy Searle, civic leader and advocate for the growth of the bioscience industry in Chicago, and Nancy Joseph-Ridge, head of global development and general manager for the Pharmaceutical Development Division at Takeda Pharmaceuticals. Illinois Governor Pat Quinn is honorary event chair, and nominating event chair is Michael Rosen, recipient of the BAM 2013 Patient Impact Legacy Award and senior vice president of the Forest City Science + Technology Group. For details and ticket information, visit: http://www.cureswithinreach.org/
About Cures Within Reach
Cures Within Reach (http://www.cureswithinreach.org/)
Director of Advancement
Cures Within Reach